Overview of the drug development pipeline for ascites
The organs of the abdomen are situated in a sac-like structure called the peritoneum. Generally, the amount of fluid in the peritoneal cavity is very less. This can vary by 20 ml or less than an ounce in women depending on the menstrual cycle. Ascites can be defined as an accumulation of fluid in the peritoneal cavity. It has been observed a variety of diseases can cause accumulation of fluid in the peritoneal cavity, resulting in ascites. The direct leakage of fluid is an after-effect of cancer that spreads to the peritoneum. In addition, there are other illnesses that cause excessive accumulation of water and sodium in the body, which eventually leads to leakage of fluid into the peritoneal cavity.
The other causes of ascites include liver disease, the inability of the organs to produce enough protein to retain fluid in the bloodstream and the obstruction to flow through the scarred cirrhotic liver. The proteins prevent the leakage of water molecules from capillary blood vessels into surrounding tissues. The liver’s ability to produce proteins is decreased by the progression of liver disease, resulting in a lack of protein in the body. Water leaks into the surrounding tissues, thus decreasing oncotic pressure. The common symptoms of ascites are abdominal distension, shortness of breath, shifting dullness, and fluid wave. Monotherapy is considered the most efficient approach for the treatment of ascites where a single drug is used to treat the particular disorder.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for ascites. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Want a bigger picture? Try a FREE sample of this report now!
Pipeline analysis report on drug development for ascites: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of ascites. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- BioVie
- Clover Biopharmaceuticals
- Kalos Therapeutics
Therapeutic assessment of the drug development pipeline for ascites by route of administration
- Intravenous
- Intraperitoneal
- Unspecified
The intravenous route of administration (ROA) involves the direct delivery of liquid substances into the vein and in the intraperitoneal technique, the drug molecules are injected directly into the peritoneum or body cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for ascites by therapy
According to this pipeline analysis report, all the molecules that are currently in the drug pipeline for ascites are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for ascites?
- What are the companies that are currently involved in the development of drug molecules for ascites?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX